

Figure 1.

1/12





Figure 2.

2/12



- Carfilzomib (CFZ) only
- Carfilzomib + Compound I-1 (0.5 μM)
- ◆--- Carfilzomib + Compound I-1 (1.0 μM)
- ▼--- Carfilzomib + Compound I-1 (2.5 μM)

Figure 3.

3/12





Figure 4.

4/12



- Mezigdomide only
- Mezigdomide + Compound I-1 (0.5 μM)
- ◆ Mezigdomide + Compound I-1 (1.0 μM)
- ▼ Mezigdomide + Compound I-1 (2.5 μM)

Figure 5.

5/12






Figure 6.

6/12

Graph A - Sequential Administration of Anti-cancer Agents




Graph B - Concurrent Administration of Anti-cancer Agents



- Mezigdomide only
- Mezigdomide + Compound I-1 (0.5 μM)
- ◆ Mezigdomide + Compound I-1 (1.0 μM)
- ▼ Mezigdomide + Compound I-1 (2.5 μM)

Figure 7.

7/12



- Pomalidomide only
- Pomalidomide + Compound I-1 (0.5 μ M)
- ◆ Pomalidomide + Compound I-1 (1.0 μ M)
- ▼ Pomalidomide + Compound I-1 (2.5 μ M)

Figure 8.

8/12





Figure 9.

9/12



Group A - Bortezomib only

Group B - Bortezomib + 100 nM Compound 47


Group C - Bortezomib + 300 nM Compound 47

Group D - Bortezomib + 600 nM Compound 47

Group E - Bortezomib + 1000 nM Compound 47

Figure 10.

10/12



BLISS Score >0: Synergistic

BLISS Score =0: Additive

Figure 11.

11/12




Figure 12.

12/12

